@MarkYarchoan That would be amazing - but who can fund and conduct a trial where you need tens of thousands of subjects (they are not patients yet) and several years to see the benefit?
Congratulations to $JNJ and Chuck Drake and team - this is impressive especially considering the AEs. May be the future for solid tumour TCEs is here. #SITC26
https://t.co/uMzTKjjIZ1
On today's #BiotechHangout, @BrianSkorney, @adamfeuerstein, @MatteisPaul & @YaronWerber will cover the election results: what a Dem-controlled Congress vs Trump's veto power means for healthcare & pharma, company news: $VRTX pove PDUFA & treatment halt controversy, $RVMD first Rasonque sales, $NBIX Vykat, $MDGL whistleblower lawsuit, Usona/$CMPS controversy, $SNY stops $NRIX STAT6 degrader program, $NVS Zolgensma update, earnings: $AMGN beats estimates, $ONC BTK degrader progress, data: pelacarsen at #AHA2026, #ASH2026 abstracts ($LEGN vs $GILD update) & much more: https://t.co/8GgJldz4Mi
It all depends on the objective. If the aim is to help anthropic develop better models for drug development to sell to the sector, buying a few smaller companies which have deep expertise in applying AI could do it.
On the other hand if their aim is to catalyze change across the industry, @LifeSciVC idea is the way. But to achieve that goal, two things need to happen: either R&D productivity needs to rise substantially leading to a flow of best in class drugs like never seen before, and/or, the margin expansion is so high that they can launch their drugs at lower prices rather than the current trend of ever rising prices = major benefit to society.
My colleague said may be in 10 years all these KM curves run at 80 and 90%. But first let’s get the drugs we already have today to patients who need them and stop pricing people out.
@GCerono@raulmarcusbruno Exactly - basically this will get better and likely reach 22 or 23 months OS, so doubling survival. But it gets harder the further you go as you start losing patients to follow up.